As of November 6, 2026, Vaxart, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 23, 2026 to October 19, 2026, naming 2 appointments. The latest filing names Raquel C. Bono, appointed (Form 8-K, October 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vaxart, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vaxart, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-23 to 2026-10-19. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Vaxart, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-19 | In | 8-K, 2026-10-19 | |||
| 2026-04-23 | In | 8-K, 2026-04-23 |
Selling to them or working with them? See who runs Vaxart, Inc. now and the warning signs.
Free to see. No signup.
Watch Vaxart, Inc.
Get an email when Vaxart, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vaxart, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vaxart, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vaxart, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Vaxart, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Vaxart, Inc., with the record behind each one.
Find candidates like senior executive at Vaxart, Inc.Every change, in the filing's words
Appointed: Raquel C. Bono
On October 16, 2026, following a recommendation by the Nominating and Governance Committee of the Board of Directors (the "Board") of Vaxart, Inc. (the "Company"), the Board appointed Raquel C. Bono, M.D., M.B.A., FACS, to serve on the Board, effective immediately, and until Dr. Bono's successor is elected and qualified, or sooner in the event of her death, resignation, or removal.
- The Board has determined that Dr. Bono meets the independence standards adopted by the Board.
- Dr. Bono has served as the Principal of RCB Consulting, LLC since October 2019 and served as Chief Executive Officer and Chief of Surgical Innovation of Medical iSight, a software-as-a-medical-device company developing three-dimensional navigational imaging for minimally invasive interventional procedures, from April 2024 to May 2026.
- From March 2020 to May 2023, at the appointment of the Governor of Washington, she served as Director of Washington State's COVID-19 Health System Response Management.
- Dr. Bono served as Chief Health Officer of Viking Cruises (NYSE: VIK) from November 2020 until December 2023.
- A board-certified general surgeon with fellowship training in trauma and critical care, Dr. Bono has served as a director of Humana Inc. (NYSE: HUM) since September 2020, where she is a member of the Audit Committee and the Clinical Quality Committee.
- She is a Senior Fellow of the Johns Hopkins University Applied Physics Laboratory, Chair of the Board of Governors of the National Military Family Association, Chair of the Council of Directors of the Henry M. Jackson Foundation for the Advancement of Military Medicine, and Vice Chair of The Leapfrog Group.
Appointed: James B. Breitmeyer
On April 23, 2026, following a recommendation by the Nominating and Governance Committee of the Board of Directors (the "Board") of Vaxart, Inc. (the "Company"), the Board appointed James B. Breitmeyer, M.D., Ph.D. to serve on the Board, effective immediately, and until Dr. Breitmeyer's successor is elected and qualified, or sooner in the event of his death, resignation, or removal.
- The Board has determined that Dr. Breitmeyer meets the independence standards adopted by the Board.
- James B. Breitmeyer, M.D., Ph.D. currently serves as the Chief Executive Officer and director of Altay Therapeutics, Inc. and as Operating Partner of SOLVE FSHD, a venture philanthropy group, since February 2026 and September 2025, respectively.
- Previously, Dr. Breitmeyer served as President and Chief Executive Officer of Oncternal Therapeutics, Inc. from February 2016 to June 2025.
- Dr. Breitmeyer is a veteran biotech executive with experience successfully starting and growing biotechnology organizations.
- He has been responsible for the development and implementation of operational and drug development strategies, as well as supervising and managing both large organizations and emerging biotechnology companies.
- He previously served as the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., a public pharmaceutical company, from August 2006 to August 2012, and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly owned subsidiary of Eli Lilly and Co., a global pharmaceutical company, from December 2001 to August 2006.
Tools for this story
Each opens in a new tab, filled in for Vaxart, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.